

## Supplementary Table-2

Sample	CD3+ (%)	CD4+ (%)	CD8+ (%)	PD-1(% of CD3 or lymphocyte)	EpCAM+ (%)	PD-L1+ (%)	CD11b+ (%)	CD206+ (%)	CD163+ (%)	FAP+ (%)	CD56+ (%)
Patient 1	NA	38.7	NA	19.2	29.3	3.03	32.3	18.8	7.9	NA	29.1
Patient 2	NA	35.3	35.6	25.9	5.06	1.28	42.5	47.2	27.5	30.7	NA
Patient 3	NA	11.8	15.9	NA	38.6	3.12	NA	14	13.3	NA	2.06
Patient 4	NA	44.7	10.2	NA	3.2	0.69	12.6	12.4	3.5	3.41	NA
Patient 5	44	8.78	39	2.07 *	3.57	2.41	37.2	42.1	8.66	NA	NA
Patient 6	47.1	17.1	22.7	5.46 *	9.18	3.18	38.6	34.5	8.85	NA	NA
Patient 7	18.9	11.1	9.59	7.15 *	71.8	1.39	59.9	21.5	3.54	NA	NA
Patient 8	NA	14.1	12	NA	48.8	14.8	29.7	21	5.48	10.4	NA
Patient 9	NA	35.4	5.95	NA	32.1	29.1	39.2	38.5	23.8	29.6	NA
Patient 10	39.80	42.30	8.60	21.30	51.60	6.57	6.48	6.38	3.15	NA	NA
Patient 11	40.8	12.2	14.2	3.91 *	5.42	3	43.6	43.6	17.6	NA	NA
Patient 12	NA	40.9	27.2	37.3	28.3	0.097	19.7	23.7	4.45	2.58	NA
Patient 13	30.8	7.88	15	2.8	11.7	22.7	46.6	NA	NA	NA	7.67
Patient 14	7.74	NA	NA	2.58	70.2	16.2	14.8	NA	NA	NA	4.32
Patient 15	6.78	14.8	4.61	4.41	28.5	41.4	53.8	NA	NA	NA	5.31

The cell types present in each ascites sample were assessed by flow cytometry and are displayed as a percentage of the total cells in the sample. The percentage of CD3+ cells were estimated by either gating on lymphocyte population (using forward and side scatter; FSC-A and SSC-A) or staining with anti-CD3 antibody. CD4+ and CD8+ population represent percentage of total lymphocytes or CD3+ population. The total percentage of cell exceeds 100% as some cells are positive for more than one marker. NA is shown if the data is unavailable. \* represents % of total cells.